HMPL 500
Alternative Names: HMPL-500Latest Information Update: 13 Dec 2024
Price :
$50 *
At a glance
- Originator HUTCHMED
- Class Antineoplastics
- Mechanism of Action Enhancer of zeste homolog 1 protein inhibitors; Enhancer of zeste homolog 2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 23 Oct 2024 Preclinical trials in Haematological malignancies in Hong Kong (PO), prior to October 2024
- 23 Oct 2024 Preclinical trials in Solid tumours in Hong Kong (PO), prior to October 2024
- 23 Oct 2024 Pharmacodynamics data from preclinical trials in Haematological malignancies and Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)